The FDA approved crizotinib for treatment of adults and children aged 1 year or older with anaplastic lymphoma kinase-positive unresectable, recurrent or refractory inflammatory myofibroblastic tumors.
Crizotinib (Xalkori, Pfizer), an ALK tyrosine kinase inhibitor, is approved for treatment of patients with metastatic non-small cell lung cancer whose tumors are ALK positive or ROS1 positive, as well as certain patients with systemic anaplastic large cell lymphoma.
The FDA based the latest approval on results of two open-label, multicenter, single-arm trials that included patients with